CNTY-341 / Century Therap - LARVOL DELTA

Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025 (GlobeNewswire) - "The event will feature discussion of CNTY-308, a CD19-targeted CAR-iT investigational cell therapy, CNTY-341, a CD19/CD22 dual-targeted CAR-iT investigational cell therapy, and the company’s first solid tumor CAR iT investigational program exploiting Nectin-4 CAR and other validated targets. Each of these programs is anchored by advanced iPSC-derived ’tunable’ CD4+/CD8+ ab T cells."

Clinical data • Oncology